Incyte (INCY) Tops Q2 EPS by 6c; Raises Jakafi Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
August 4, 2015 7:00 AM EDT$142 million of 2015 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 69 percent growth over the same period last year 2015 guidance for Jakafi net product revenues increased to range of $560 million to $575 million, driven by strong underlying demand Positive results from two pivotal trials of baricitinib in rheumatoid arthritis presented at EULAR Multiple abstracts presented at ASCO and EHA, demonstrating continued progress across broad clinical portfolio
Conference Call and Webcast Scheduled Today at 10:00 a.m. ET
... More
